Versana Balance
GE Medical Systems Ultrasound and Primary Care Diagnostics, • Radiology • 05/11/2022
Device Purpose
The Versana Balance is a mobile diagnostic ultrasound system designed for comprehensive imaging, measurement, and analysis across diverse clinical applications using multiple modes like Doppler, 3D/4D, and elastography. It leverages updated hardware and advanced software, including AI-driven tools and specialized reporting features, to enhance diagnostic capabilities and workflow for healthcare professionals.
Summary
The Versana Balance is a general-purpose diagnostic ultrasound system designed for use by qualified healthcare professionals in hospital or medical clinic settings. It is a mobile console equipped with an operator control panel, display monitor, various transducers (convex, linear, sector, mechanical 4D), and an internal battery for portable operation. The system supports a wide array of clinical applications, including fetal/obstetrics, abdominal, gynecology, urology, pediatric, small parts (breast, testes, thyroid), adult and pediatric cardiac, vascular/peripheral vascular, musculoskeletal (conventional and superficial), thoracic/pleural, transcranial, transrectal, transvaginal imaging, and interventional guidance for procedures like tissue biopsy and fluid drainage. It offers multiple imaging modes such as B-mode, M-mode, PW/CW Doppler, Color Doppler, Power Doppler, Harmonic Imaging, 3D/4D imaging, and Elastography. Key technological enhancements include the addition of new transducers (L8-18i-RS, 12S-RS) and the extension of Elastography mode to several existing transducers. Software updates introduce features like 'Whizz Label' (an AI tool for anatomical identification), 'LI-RADS' (for standardized liver imaging reporting), 'Probe Check' (for transducer performance evaluation), 'Whizz Color Flow' (automatic color flow optimization), Lateral Gain Compensation (LGC), 'VOCAL' (for 3D/4D volume calculation), 'Standby mode' for fast boot-up, and 'V-Live' for enhanced 3D/4D visualization. The system also features updated internal computer components, an optional multi-touch panel, cable tray, and barcode reader. Data management is facilitated through DVD, USB, LAN, and optional WiFi/Bluetooth connectivity. The device has undergone non-clinical testing for acoustic output, biocompatibility, safety, and compliance with relevant medical device standards.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the newly added transducers, L8-18i-RS and 12S-RS, compare to existing transducers in specific clinical applications such as musculoskeletal or pediatric cardiac imaging?; What is the measurable impact of the 'Whizz Label' AI feature on reducing scan time or improving consistency in anatomical identification across different users?; Can the 'LI-RADS' software feature be customized or integrated with existing hospital reporting systems for liver imaging?; What are the specific advantages or limitations of the 'VOCAL' volume calculation feature in complex anatomical structures compared to other volumetric assessment methods?; How does the 'Whizz Color Flow' automated optimization perform in challenging cases, such as patients with high BMI or deep-seated vessels, compared to manual adjustments by experienced sonographers?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, ML-BOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly